Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | MPO | P05164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23745580 | 0.86 | SOS1 (0.50) | SOS1ACHEBACE1MPO | |
| SCHEMBL23745605 | 0.86 | SOS1 (0.46) | SOS1PDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL23721946 | 0.86 | SOS1 (0.49) | SOS1ACHEBACE1MPO | |
| SCHEMBL23745615 | 0.85 | SOS1 (0.44) | SOS1PDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL23722190 | 0.85 | SOS1 (0.45) | SOS1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23745826 | 0.85 | SOS1 (0.51) | SOS1MPO | |
| SCHEMBL23745456 | 0.84 | SOS1 (0.50) | SOS1MPO | |
| Hydrochloric Acid SCHEMBL23722094 | 0.84 | SOS1 (0.50) | SOS1MPO | |
| Hydrochloric Acid SCHEMBL23722150 | 0.83 | SOS1 (0.49) | SOS1MPO | |
| SCHEMBL23745849 | 0.83 | CPB2 (0.32) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2021-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | FDPS, FPR1, F12 | SOS1 2902/4885ACHE 813/4885BACE1 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.